Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years Old

Inclusion Criteria: * Subjects who the investigator believes can and will comply with the requirements of the protocol. Or subjects who the investigator believes that parent(s)/Legally Acceptable Representative(s) can and will comply with the requirements of the protocol. * Korean male or female subject between, and including, 18 and 60 years of age at the time of the first vaccination. * Written informed consent obtained from the subject/ from the parent(s)/ Legally Acceptable Representative(s). * Healthy subjects or free of acute aggravation of the health status as established by medical history and clinical examination before entering into the study. * Access to a consistent means of telephone contact, which may be either in the home or at the workplace, land line or mobile, but NOT a pay phone or other multiple-user device. * Female subjects of non-childbearing potential may be enrolled in the study. * Female subjects of childbearing potential may be enrolled in the study, if the subject has practiced adequate contraception for 30 days prior to vaccination, has a negative pregnancy test on the day of vaccination, and has agreed to continue adequate contraception during the entire treatment period and for two months after completion of the vaccination series. Exclusion Criteria: * Use of any investigational or non-registered product other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period. * Acute dis…